2024 Q2 Form 10-Q Financial Statement
#000149315224019247 Filed on May 14, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $4.054M | $3.419M | $3.857M |
| YoY Change | 19.41% | -11.36% | 11.47% |
| Cost Of Revenue | $1.403M | $100.0K | $100.0K |
| YoY Change | 1303.0% | 0.0% | -90.85% |
| Gross Profit | $2.651M | $1.937M | $2.337M |
| YoY Change | 26.36% | -17.12% | -1.27% |
| Gross Profit Margin | 65.39% | 56.65% | 60.59% |
| Selling, General & Admin | $4.442M | $5.576M | $7.167M |
| YoY Change | -31.31% | -22.2% | -20.61% |
| % of Gross Profit | 167.56% | 287.87% | 306.68% |
| Research & Development | $100.0K | $100.0K | |
| YoY Change | 0.0% | 0.0% | |
| % of Gross Profit | 5.16% | 4.28% | |
| Depreciation & Amortization | $100.0K | $146.0K | $175.0K |
| YoY Change | -32.43% | -16.57% | 326.83% |
| % of Gross Profit | 3.77% | 7.54% | 7.49% |
| Operating Expenses | $4.587M | $5.722M | $7.342M |
| YoY Change | -30.66% | -22.06% | -20.11% |
| Operating Profit | -$1.936M | -$3.785M | -$5.005M |
| YoY Change | -57.14% | -24.38% | -26.65% |
| Interest Expense | |||
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | -$22.00K | -$1.000K | $51.00K |
| YoY Change | -90.22% | -101.96% | 142.86% |
| Pretax Income | -$1.930M | -$3.763M | -$1.703M |
| YoY Change | -65.09% | 120.96% | -69.12% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$1.930M | -$3.763M | -$1.703M |
| YoY Change | -65.09% | 120.96% | -69.12% |
| Net Earnings / Revenue | -47.61% | -110.06% | -44.15% |
| Basic Earnings Per Share | -$0.60 | -$1.63 | -$0.07 |
| Diluted Earnings Per Share | -$0.60 | -$1.63 | -$0.07 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 3.227M shares | 2.731M shares | 29.68M shares |
| Diluted Shares Outstanding | 3.228M shares | 2.308M shares | 990.7K shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $6.903M | $2.611M | $7.046M |
| YoY Change | 75.11% | -62.94% | -60.48% |
| Cash & Equivalents | $6.900M | $2.600M | $7.000M |
| Short-Term Investments | |||
| Other Short-Term Assets | $554.0K | $475.0K | $1.346M |
| YoY Change | -48.37% | -64.71% | -51.43% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $395.0K | $525.0K | $321.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $7.852M | $3.611M | $8.713M |
| YoY Change | 46.99% | -58.56% | -59.66% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $3.259M | $3.332M | $3.157M |
| YoY Change | -0.24% | 5.54% | -28.69% |
| Goodwill | $2.843M | $2.843M | $2.843M |
| YoY Change | 0.0% | 0.0% | |
| Intangibles | $395.0K | $408.0K | $458.0K |
| YoY Change | -11.24% | -10.92% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $276.0K | $308.0K | $308.0K |
| YoY Change | -10.39% | 0.0% | -12.99% |
| Total Long-Term Assets | $7.990M | $8.193M | $8.387M |
| YoY Change | -4.96% | -2.31% | 5.43% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $7.852M | $3.611M | $8.713M |
| Total Long-Term Assets | $7.990M | $8.193M | $8.387M |
| Total Assets | $15.84M | $11.80M | $17.10M |
| YoY Change | 15.22% | -30.97% | -42.14% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.028M | $2.499M | $1.495M |
| YoY Change | 53.06% | 67.16% | 70.47% |
| Accrued Expenses | $2.185M | $2.466M | $1.940M |
| YoY Change | 12.11% | 27.11% | -45.03% |
| Deferred Revenue | $1.795M | $2.398M | $2.647M |
| YoY Change | -23.91% | -9.41% | |
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $6.643M | $8.070M | $7.975M |
| YoY Change | -21.29% | 1.19% | 16.41% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $2.852M | $3.152M | $2.132M |
| YoY Change | -10.96% | 47.84% | 15.24% |
| Total Long-Term Liabilities | $2.852M | $3.152M | $2.132M |
| YoY Change | -10.96% | 47.84% | 15.24% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $6.643M | $8.070M | $7.975M |
| Total Long-Term Liabilities | $2.852M | $3.152M | $2.132M |
| Total Liabilities | $9.500M | $11.20M | $10.10M |
| YoY Change | -18.1% | 10.89% | 16.08% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$98.70M | -$96.80M | -$81.20M |
| YoY Change | 13.84% | 19.21% | |
| Common Stock | $0.00 | $0.00 | $3.000K |
| YoY Change | -100.0% | -100.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $6.347M | $582.0K | $6.993M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $15.84M | $11.80M | $17.10M |
| YoY Change | 15.22% | -30.97% | -42.14% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.930M | -$3.763M | -$1.703M |
| YoY Change | -65.09% | 120.96% | -69.12% |
| Depreciation, Depletion And Amortization | $100.0K | $146.0K | $175.0K |
| YoY Change | -32.43% | -16.57% | 326.83% |
| Cash From Operating Activities | -$3.048M | -$2.500M | -$3.500M |
| YoY Change | 6.61% | -28.57% | -42.45% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $60.00K | $151.0K | $239.0K |
| YoY Change | -75.51% | -36.82% | -299.17% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$50.00K | ||
| YoY Change | |||
| Cash From Investing Activities | -$60.00K | -$151.0K | -$289.0K |
| YoY Change | -75.51% | -47.75% | 140.83% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 7.400M | $3.635M | $7.355M |
| YoY Change | -50.58% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -3.048M | -$2.500M | -$3.500M |
| Cash From Investing Activities | -60.00K | -$151.0K | -$289.0K |
| Cash From Financing Activities | 7.400M | $3.635M | $7.355M |
| Net Change In Cash | 4.292M | $968.0K | $3.527M |
| YoY Change | -238.27% | -72.55% | |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$3.048M | -$2.500M | -$3.500M |
| Capital Expenditures | $60.00K | $151.0K | $239.0K |
| Free Cash Flow | -$3.108M | -$2.651M | -$3.739M |
| YoY Change | 0.13% | -29.1% | -37.29% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2024Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2024Q1 | VVOS |
Excess Warrant Fair Value
ExcessWarrantFairValue
|
usd | |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
usd | |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
usd | |
| CY2024Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
usd | |
| CY2024Q1 | VVOS |
Excess Warrant Fair Value
ExcessWarrantFairValue
|
usd | |
| CY2024Q1 | us-gaap |
Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
|
usd | |
| CY2024Q1 | VVOS |
Fair Value Of Warrants Issued In Asset Purchase
FairValueOfWarrantsIssuedInAssetPurchase
|
usd | |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3419000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3857000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
|
1482000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
|
1520000 | usd |
| CY2024Q1 | us-gaap |
Gross Profit
GrossProfit
|
1937000 | usd |
| CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
2337000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4921000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6537000 | usd |
| CY2024Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
655000 | usd |
| CY2023Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
630000 | usd |
| CY2024Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
146000 | usd |
| CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
175000 | usd |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
5722000 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
7342000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3785000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5005000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
51000 | usd |
| CY2023Q1 | VVOS |
Excess Warrant Fair Value
ExcessWarrantFairValue
|
6453000 | usd |
| CY2024Q1 | VVOS |
Net Of Warrant Liability Issuance Costs
NetOfWarrantLiabilityIssuanceCosts
|
645000 | usd |
| CY2023Q1 | VVOS |
Net Of Warrant Liability Issuance Costs
NetOfWarrantLiabilityIssuanceCosts
|
645000 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-9628000 | usd |
| CY2024Q1 | us-gaap |
Other Income
OtherIncome
|
23000 | usd |
| CY2023Q1 | us-gaap |
Other Income
OtherIncome
|
76000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3763000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1703000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3763000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1703000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.63 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.63 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.72 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.72 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
2308154 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2308154 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
990669 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
990669 | shares |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4801000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
|
116000 | usd |
| CY2023Q1 | VVOS |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
2848000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
625000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
306000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1703000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6993000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
411000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
411000 | usd |
| CY2024Q1 | VVOS |
Stock Issued During Period Value Warrants Exercised Net Of Issuance Costs
StockIssuedDuringPeriodValueWarrantsExercisedNetOfIssuanceCosts
|
3635000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
6000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
293000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3763000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
582000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
582000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3763000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1703000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
293000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
306000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
146000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
175000 | usd |
| CY2024Q1 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
6000 | usd |
| CY2023Q1 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
625000 | usd |
| CY2024Q1 | VVOS |
Net Of Warrant Liability Issuance Costs
NetOfWarrantLiabilityIssuanceCosts
|
645000 | usd |
| CY2023Q1 | VVOS |
Net Of Warrant Liability Issuance Costs
NetOfWarrantLiabilityIssuanceCosts
|
645000 | usd |
| CY2023Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
9628000 | usd |
| CY2023Q1 | VVOS |
Excess Warrant Fair Value
ExcessWarrantFairValue
|
6453000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
324000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-136000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-141000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-102000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-30000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-25000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
|
-4000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
|
-79000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
354000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
84000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
132000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
28000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
21000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-31000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
504000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-140000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2516000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3539000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
151000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
239000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
|
50000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-151000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-289000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
3941000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
8000000 | usd |
| CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
306000 | usd |
| CY2023Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
645000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3635000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7355000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
968000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
3527000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
1643000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
3519000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2611000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
7046000 | usd |
| CY2023Q1 | VVOS |
Fair Value Of Warrants Issued In Asset Purchase
FairValueOfWarrantsIssuedInAssetPurchase
|
116000 | usd |
| CY2020Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2023Q4 | us-gaap |
Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
|
1-for-25 | |
| CY2024Q1 | VVOS |
Percentage Of Revenue
PercentageOfRevenue
|
0.80 | pure |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_84C_eus-gaap--UseOfEstimates_zN1P7WCvhlYh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zwES3eCvTiIe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on existing facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, assessing collectability on accounts receivable, the determination of customer life and breakage related to recognizing revenue for VIP contracts, impairment of goodwill and long-lived assets; valuation assumptions for assets acquired in asset acquisitions; valuation assumptions for stock options, warrants, warrant liabilities and equity instruments issued for goods or services; deferred income taxes and the related valuation allowances; and the evaluation and measurement of contingencies. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | VVOS |
Warrant Accounting Policy Textblock
WarrantAccountingPolicyTextblock
|
<p id="xdx_84F_ecustom--WarrantAccountingPolicyTextblock_zoKXKln1xUA2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zdMVqYDXzVye">Warrant Accounting </span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its warrants and financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with <i>ASC 815, Derivatives and Hedging</i>. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as liabilities and other financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using the Black-Scholes model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> | |
| CY2024Q1 | us-gaap |
Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
|
P5Y | |
| CY2024Q1 | VVOS |
Gross Receipt Percentage
GrossReceiptPercentage
|
0.50 | pure |
| CY2024Q1 | VVOS |
Employee Retain Description
EmployeeRetainDescription
|
Healthcare plan expenses were not included in the analysis, although they are eligible if an employee has paid health insurance through their paycheck. Section 2301(c)(5)(B) of the CARES Act provides that “wages” include amounts paid by an eligible employer to provide and maintain a group health plan (as defined in section 5000(b)(1) of the Code), but only to the extent that the amounts are excluded from the gross income of employees by reason of section 106(a) of the Code. The Company pays the first $500 of healthcare insurance for each employee, which generally covers the monthly cost of their insurance. Because of this, the Company conservatively did not include any of the cost of insurance in its analysis. Additionally, PPP loan amounts were deducted from the amount of total wages paid before calculating the qualified ERTC wages. The Company applied for the ERTC using Vivos Therapeutics Inc.’s payroll, which covers 95% of its employees | |
| CY2024Q1 | VVOS |
Eligible Tax Credit Description
EligibleTaxCreditDescription
|
As indicated above, for 2020, companies were eligible for a credit equal to 50 percent of the first ten thousand of qualified wages paid per employee in the aggregate of each eligible quarter. Therefore, the maximum ERTC for the Company for 2020 is five thousand ($5,000) per employee. For the second and fourth quarters of 2020, the total eligible credit was limited to approximately $0.5 million | |
| CY2024Q1 | VVOS |
Credit Percentage
CreditPercentage
|
0.70 | pure |
| CY2024Q1 | VVOS |
Credit Limit
CreditLimit
|
700000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
|
1200000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
100000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
100000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
|
greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3800000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1700000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-96800000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2500000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3500000 | usd |
| CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
11200000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2600000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3419000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3857000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3038000 | usd |
| CY2022Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3038000 | usd |
| CY2024Q1 | VVOS |
Contract With Customer Liability During The Period
ContractWithCustomerLiabilityDuringThePeriod
|
855000 | usd |
| CY2023Q1 | VVOS |
Contract With Customer Liability During The Period
ContractWithCustomerLiabilityDuringThePeriod
|
1225000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
-962000 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
-1396000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
2931000 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
2867000 | usd |
| CY2024Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
2400000 | usd |
| CY2024Q1 | VVOS |
Revenue From Breakage On Contract Liabilities
RevenueFromBreakageOnContractLiabilities
|
400000 | usd |
| CY2023Q1 | VVOS |
Revenue From Breakage On Contract Liabilities
RevenueFromBreakageOnContractLiabilities
|
300000 | usd |
| CY2023Q4 | us-gaap |
Receivables From Customers
ReceivablesFromCustomers
|
200000 | usd |
| CY2024Q1 | us-gaap |
Receivables From Customers
ReceivablesFromCustomers
|
500000 | usd |
| CY2024Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
200000 | usd |
| CY2023Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
200000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
100000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
100000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
5791000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
5640000 | usd |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2459000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2326000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3332000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3314000 | usd |
| CY2024Q1 | us-gaap |
Area Of Land
AreaOfLand
|
15000 | sqft |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
100000 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
200000 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
2800000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
2800000 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
2843000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
2843000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2659000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2659000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2251000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2239000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
408000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
420000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
100000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
38000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
50000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
35000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
29000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
29000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
227000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
408000 | usd |
| CY2024Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1328000 | usd |
| CY2023Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1498000 | usd |
| CY2024Q1 | VVOS |
Accrued Legal And Other
AccruedLegalAndOther
|
1098000 | usd |
| CY2023Q4 | VVOS |
Accrued Legal And Other
AccruedLegalAndOther
|
798000 | usd |
| CY2024Q1 | VVOS |
Accrued Lab Rebate Liabilities Current
AccruedLabRebateLiabilitiesCurrent
|
40000 | usd |
| CY2023Q4 | VVOS |
Accrued Lab Rebate Liabilities Current
AccruedLabRebateLiabilitiesCurrent
|
38000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2466000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2334000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2023Q1 | us-gaap |
Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
|
10000 | shares |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
|
50000 | usd |
| CY2023Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
200000 | usd |
| CY2023Q1 | us-gaap |
Cash
Cash
|
200000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
100000 | usd |
| CY2023Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
16000 | shares |
| CY2023Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
15.25 | |
| CY2023Q4 | us-gaap |
Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
|
1-for-25 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
0 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
2821000 | shares |
| CY2023Q4 | VVOS |
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
|
13.15 | |
| CY2023 | VVOS |
Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y7M6D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
|
1394000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
|
11000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
2887000 | shares |
| CY2024Q1 | VVOS |
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
|
7.83 | |
| CY2024Q1 | VVOS |
Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P3Y9M18D | |
| CY2024Q1 | VVOS |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
|
2833000 | shares |
| CY2024Q1 | VVOS |
Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
|
7.60 | |
| CY2024Q1 | VVOS |
Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2
|
P3Y9M18D | |
| CY2024Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
0 | usd |
| CY2024Q1 | VVOS |
Warrants And Rights Exercisable
WarrantsAndRightsExercisable
|
0 | usd |
| CY2024Q1 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | pure |
| CY2023Q1 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | pure |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
123000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
130000 | usd |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
123000 | usd |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
130000 | usd |
| CY2024Q1 | us-gaap |
Payments For Rent
PaymentsForRent
|
100000 | usd |
| CY2023Q1 | us-gaap |
Payments For Rent
PaymentsForRent
|
100000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y6M | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.084 | pure |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
153000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
468000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
594000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
507000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
493000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
133000 | usd |
| CY2024Q1 | VVOS |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
7000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
2202000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
320000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1882000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3763000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1703000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3763000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1703000 | usd |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2308154 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
990669 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.63 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.63 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.72 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.72 | |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3014 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
620 | shares |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2600000 | usd |
